Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
NuVasive revenue
NuVasive's revenue is $1.2 billion.
What is NuVasive's revenue?
- NuVasive has 2,800 employees, and the revenue per employee ratio is $429,265.
- NuVasive's peak quarterly revenue was $317.8M in 2023(q2).
- NuVasive peak revenue was $1.2B in 2022.
- NuVasive annual revenue for 2021 was 1.1B, 8.41% growth from 2020.
- NuVasive annual revenue for 2022 was 1.2B, 5.53% growth from 2021.
- NuVasive's revenue growth from 2003 to 2022 is 5,205.42%.
On this page
Zippia finds jobs where you're a top candidate and applies on your behalf.
NuVasive historical revenue
NuVasive's peak revenue was $1.2B in 2022. The peak quarterly revenue was $317.8M in 2023(q2).
NuVasive's revenue increased from $22.7m in 2003 to $1.2B currently. That's a 5,205.42% change in annual revenue.
NuVasive annual revenue
NuVasive annual revenue over time
| Fiscal year / year | NuVasive revenue |
|---|---|
| 2009 | $370.3M |
| 2010 | $478.2M |
| 2011 | $540.5M |
| 2012 | $620.3M |
| 2013 | $685.2M |
| 2014 | $762.4M |
| 2015 | $811.1M |
| 2016 | $962.1M |
| 2017 | $1.0B |
| 2018 | $1.1B |
| 2019 | $1.2B |
| 2020 | $1.1B |
| 2021 | $1.1B |
| 2022 | $1.2B |
How accurately did NuVasive's revenue projections match actual performance?
NuVasive annual growth
NuVasive saw the greatest revenue growth in 2004, when revenue increased by 72.54%.
NuVasive had the lowest revenue growth in 2020, when revenue changed by -10.06%.
NuVasive annual growth rate over time
| Year | NuVasive growth |
|---|---|
| 2009 | 48%↑ |
| 2010 | 29%↑ |
| 2011 | 13%↑ |
| 2012 | 15%↑ |
| 2013 | 10%↑ |
| 2014 | 11%↑ |
| 2015 | 6%↑ |
| 2016 | 19%↑ |
| 2017 | 7%↑ |
| 2018 | 7%↑ |
| 2019 | 6%↑ |
| 2020 | -10%↓ |
| 2021 | 8%↑ |
| 2022 | 6%↑ |
NuVasive quarterly revenue over time
- Q1
- Q2
- Q3
- Q4
NuVasive quarterly growth rate over time
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2009 | $80.0M | $88.5M | $94.9M | $106.9M |
| 2010 | $109.1M | $119.6M | $120.3M | $129.3M |
| 2011 | $124.5M | $133.0M | $132.9M | $150.2M |
| 2012 | $151.7M | $154.4M | $148.4M | $165.8M |
| 2013 | $159.5M | $165.7M | $169.2M | $190.8M |
| 2014 | $177.5M | $190.7M | $189.9M | $204.3M |
| 2015 | $192.4M | $202.9M | $200.5M | $215.3M |
| 2016 | $215.1M | $236.2M | $239.6M | $271.2M |
| 2017 | $249.0M | $259.4M | $247.1M | $271.2M |
| 2018 | $260.5M | $281.6M | $271.3M | $288.3M |
| 2019 | $274.8M | $292.1M | $290.8M | $310.4M |
| 2020 | $259.9M | $203.6M | $295.3M | $291.8M |
| 2021 | $271.2M | $294.8M | $270.8M | $302.1M |
| 2022 | $290.8M | $310.5M | $295.3M | $305.4M |
| 2023 | $307.7M | $317.8M | - | - |
NuVasive jobs nearby
Do you work at NuVasive?
Did NuVasive meet its revenue projections?
NuVasive financial information
| CEO | Chris Barry |
| Industry | Pharmaceuticals, Biotechnology & Life Sciences |
| Company Type | Public |
| Employees Number | 2,800 |
| Date Founded | 1997 |
| Headquarters | San Diego, California |
| Number of Locations | 10 |
| Revenue | $1.2B |
| Net Income | $40,407,000 |
| Gross Proft | $865.4M (2022) |
| EBITDA | $116.4M (2022) |
| PE Ratio | 62.52 |
| Tax Rate | 0.2% |
| Market Capitalization | $2.5B |
| Total Assets | $2,224,505,000 |
| Ticker | NUVA |
NuVasive jobs you might like
NuVasive financing
NuVasive received early financing of $15.0M on 2002-06-01.
| Series | Round size | Date |
|---|---|---|
| Series Unknown | $15M | 06/2002 |
| Series Unknown | $9.8M | 05/2004 |
| Post Ipo Equity | $40.5M | 10/2011 |
NuVasive investors
| Investors | Security type |
|---|---|
| William Blair | Series Unknown |
| Enterprise Partners | Series Unknown |
| Pappas Ventures | Series Unknown |
| Kleiner Perkins | Series Unknown |
| Domain Associates | Series Unknown |
NuVasive competitors
NuVasive's top competitor, Gilead Sciences, earned an annual revenue of $28.8B.
NuVasive's smallest competitor is Ardent Technologies with revenue of $1.6M last year.
| Company name | Average salary | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| Stryker | $69,470 | $22.6B | 43,000 | 1,852 |
| Boston Scientific | $60,291 | $16.7B | 36,000 | 711 |
| CryoLife | $54,541 | $253.2M | 1,000 | - |
| Intersect ENT | $67,446 | $106.7M | 393 | - |
| Abiomed | $99,022 | $1.0B | 1,536 | - |
| Varian Medical Systems | $104,569 | $3.2B | 10,000 | 3 |
| Tandem Diabetes Care | $62,371 | $940.2M | 1,500 | 1 |
| Danaher | $65,463 | $23.9B | 80,000 | 1,239 |
| Gilead Sciences | $99,828 | $28.8B | 11,800 | 569 |
| Globus Medical | $78,407 | $2.5B | 1,800 | 332 |
Search for jobs
Related company revenues
Working at related companies
Related company jobs
NuVasive highest paying jobs
Zippia gives an in-depth look into the details of NuVasive, including salaries, political affiliations, employee data, and more, in order to inform job seekers about NuVasive. The employee data is based on information from people who have self-reported their past or current employments at NuVasive. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by NuVasive. The data presented on this page does not represent the view of NuVasive and its employees or that of Zippia.
NuVasive may also be known as or be related to NUVASIVE INC, NuVasive, NuVasive Inc, NuVasive Inc., NuVasive, Inc. and Nuvasive, Inc.